AIM: To determine the presence of RASSF1A promoter methylation in tumorous and non-tumorous tissues of breast cancer. METHODS: Methylation-specific PCR was used to detect RASSF1A methylation in DNA extracted from tumorous and paired non-tumorous tissues of 40 breast cancer patients. The associations of RASSF1A hypermethylation with clinicopathological characteristics in tumorous and non-tumorous breast tissues were analysed. RESULTS: RASSF1A promoter hypermethylation was detected in 38 of the 40 breast cancer tissues (95%) and 37 of the paired non-tumorous tissues (92.5%). When compared with the non-tumorous tissues, aberrant methylation was detected to be higher in 24 of the tumorous tissues (60%). The latter was found to be associated with lower histological grade tumours (p=0.048). CONCLUSION: RASSF1A promoter hypermethylation occurred at a high frequency in breast cancer tumorous and non-tumorous tissues; the majority of tumours have a higher level of methylation status when compared with non-tumorous tissues. This supports the notion that RASSF1A methylation is an early and premalignant alteration.
AIM: To determine the presence of RASSF1A promoter methylation in tumorous and non-tumorous tissues of breast cancer. METHODS: Methylation-specific PCR was used to detect RASSF1A methylation in DNA extracted from tumorous and paired non-tumorous tissues of 40 breast cancerpatients. The associations of RASSF1A hypermethylation with clinicopathological characteristics in tumorous and non-tumorous breast tissues were analysed. RESULTS:RASSF1A promoter hypermethylation was detected in 38 of the 40 breast cancer tissues (95%) and 37 of the paired non-tumorous tissues (92.5%). When compared with the non-tumorous tissues, aberrant methylation was detected to be higher in 24 of the tumorous tissues (60%). The latter was found to be associated with lower histological grade tumours (p=0.048). CONCLUSION:RASSF1A promoter hypermethylation occurred at a high frequency in breast cancer tumorous and non-tumorous tissues; the majority of tumours have a higher level of methylation status when compared with non-tumorous tissues. This supports the notion that RASSF1A methylation is an early and premalignant alteration.
Authors: Eva Jezkova; Karol Kajo; Pavol Zubor; Marian Grendar; Bibiana Malicherova; Andrea Mendelova; Karol Dokus; Zora Lasabova; Lukas Plank; Jan Danko Journal: Tumour Biol Date: 2016-10-15
Authors: Hetty E Carraway; Shelun Wang; Amanda Blackford; Mingzho Guo; Penny Powers; Stacie Jeter; Nancy E Davidson; Pedram Argani; Kyle Terrell; James G Herman; Julie R Lange Journal: Breast Cancer Res Treat Date: 2008-04-11 Impact factor: 4.872
Authors: Rosalyn R Ram; Saurabh Mendiratta; Brian O Bodemann; Michael J Torres; Ugur Eskiocak; Michael A White Journal: Mol Cell Biol Date: 2014-04-14 Impact factor: 4.272
Authors: Ning Yi Yap; Retnagowri Rajandram; Keng Lim Ng; Jayalakshmi Pailoor; Ahmad Fadzli; Glenda Carolyn Gobe Journal: Biomed Res Int Date: 2015-09-13 Impact factor: 3.411
Authors: Dan Cao; Ye Chen; Yuan Tang; Xing-Chen Peng; Hang Dong; Long-Hao Li; Ke Cheng; Jun Ge; Ji-Yan Liu Journal: Biomed Res Int Date: 2013-06-22 Impact factor: 3.411